Issue link: https://www.e-digitaleditions.com/i/1463386
Inhalation April 2022 7 organizations, with separate gov- ernance and distinct membership. As appropriate, the groups coordi- nate and will likely collaborate on issues relevant to the transition to novel medical propellants. Contact IPAC IPAC's current members are Astra- Zeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kindeva, Organon and Teva. Its website provides details on activities and resources: w w w. ipacinhaler.org. involved or obtaining communica- tions materials, please contact IPAC through its website, listed below. IPAC-RS e International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS), was launched in 1998 with a mission to enhance the quality and availability of orally inhaled and nasal drug products (OINDPs). IPAC-RS encourages scientifically driven advancements related to the development and regulation of OINDPs. IPAC and IPAC-RS are autonomous • IPAC actively engaged with the US Environmental Protection Agency (EPA), the UK's Defra, and the European Commis- sion (DG Clima, DG Sante) on regulatory proposals with implications for HFCs as med- ical propellants. IPAC prepared in-depth comments and inter- vened during public consulta- tion processes in the US, UK and Europe. • IPAC is an active member of the UK National Health Ser- vice (NHS) Inhalers Working Group—a multi-stakeholder col- laboration aimed at meeting the NHS's net zero commitments. IPAC presented to the Working Group several times and engaged stakeholder members. Initiatives spotlight: IPAC inhaler return campaign in the UK In July 2021, IPAC launched a com- munications campaign in the UK to encourage patients to return their used or surplus inhalers to phar- macies for environmentally appro- priate handling in the medicines waste stream. Under the existing NHS infrastructure, individuals who are no longer in need of their inhalers may return them to UK pharmacies for high temperature incineration. e process ensures that the propellant is destroyed and not emitted into the atmosphere. IPAC, in collaboration with patients (Asthma UK/British Lung Foun- dation) and community pharma- cies (PSNC), developed the Inhaler Return Campaign to help protect the environment by encouraging this safer means of inhaler disposal. e communications campaign leverages social media to raise awareness. It consists of graphics, available in English and Welsh, as well as sample language that can be shared with the materials. e cam- paign was well-received in 2021 and IPAC looks forward to continuing the campaign throughout 2022. For questions about the Inhaler Return Campaign, becoming